The US Food and Drug Administration (FDA) on Thursday approved the first medication for people with a severe type of non-alcoholic fatty liver disease.

Madrigal Pharmaceuticals’ Rezdiffra was shown to improve liver scarring in a clinical trial involving hundreds of people with non-alcoholic steatohepatitis (NASH), the worst form of the condition caused by a buildup of fat in the liver.

“Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage,” said the FDA’s Nikolay Nikolov.

“Today’s approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise.”

  • ThoGot
    link
    fedilink
    English
    arrow-up
    3
    arrow-down
    1
    ·
    3 months ago

    and also probably high consumption of fructose

    • GBU_28
      link
      fedilink
      English
      arrow-up
      3
      ·
      3 months ago

      That’s a cause of the above conditions